Tejasvene Ramesh

Tejasvene Ramesh

Auto-generated profile, based on publicly available information

Tejasvene Ramesh

Center for Personalized Cancer Therapy, University of Massachusetts Boston, Boston, USA

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 August 2024 in Cell
Verified
Journal Article
Closed access
DDDhrithi Deshpande
Dhrithi Deshpande
KCKarishma Chhugani
Karishma Chhugani
TRTejasvene Ramesh
Tejasvene Ramesh
MPMatteo Pellegrini
Matteo Pellegrini
SSSagiv Shifman
Sagiv Shifman
SMSerghei Mangul
Serghei Mangul

1 October 2005 in Separation Science and Technology
Verified
Journal Article
Closed access
JLJ. W. Lee
J. W. Lee
JCJ. I. Chun
J. I. Chun
HJH. J. Jung
H. J. Jung
DKDong-Heui Kwak
Dong-Heui Kwak
TRT. Ramesh
T. Ramesh
HMH. Moon
H. Moon
Membrane fouling is the main limitation of water and wastewater treatment. Coagulation and adsorption can remove organic materials which play an important role in fouling phenomena. Thus, this study focused on the comparison of the hybrid process of coagulation and adsorption coupled with microfiltration (MF) membrane for the secondary domestic wastewater from an apartment complex in Gwangju city, South Korea. Coagulation and adsorption were adopted as a pretreatment method prior to MF treatment. Three different powdered activated carbon (PAC) and ferric chloride were used as an adsorbent and as a coagulant. MF was operated in a submerged mode using hollow fiber polyethylene membrane with pore size of 0.4 µm for the separation of suspended organic solids resulted from coagulation or PAC particles, which are used for adsorbing organics dissolved in wastewater. Prior to study on the hybrid system, the performance of coagulation and adsorption processes were optimized individually for the removal of organics. Then, the overall performance for the hybrid system of coagulation/MF and PAC/MF was evaluated based on TOC removal, turbidity removal, and flux decline. It was found that the combined coagulation/MF and PAC/MF showed similar performance for TOC removal while coagulation/MF resulted in a significant decrease of the flux decline.

9 September 2025 in Genome Biology
Verified
Journal Article
Open access
PDF file
YHYu-Ning Huang
Yu-Ning Huang
PJPooja Vinod Jaiswal
Pooja Vinod Jaiswal
ARAnushka Rajes
Anushka Rajes
AYAnushka Yadav
Anushka Yadav
DYDottie Yu
Dottie Yu
SMSerghei Mangul
Serghei Mangul
Recent advances in high-throughput sequencing technologies have enabled the collection and sharing of a massive amount of omics data, along with its associated metadata—descriptive information that contextualizes the data, including phenotypic traits and experimental design. Enhancing metadata availability is critical to ensure data reusability and reproducibility and to facilitate novel biomedical discoveries through effective data reuse. Yet, incomplete metadata accompanying public omics data may hinder reproducibility and reusability and limit secondary analyses. Our study assesses the completeness of metadata in over 253 scientific studies, covering more than 164,000 samples from both human and non-human mammalian studies. We find that over 25% of critical metadata are omitted, with only 74.8% of relevant phenotypes available in publications or public repositories. Notably, public repositories alone contain 62% of the phenotypes, surpassing the textual content of publications by 3.5%. Only 11.5% of studies completely shared all phenotypes, while 37.9% shared less than 40% of the phenotypes. Additionally, studies with non-human samples are more likely to include complete metadata compared to human studies. Similar trends are observed in an extended dataset comprising 61,000 studies and 2.1 million samples from the Gene Expression Omnibus (GEO) data repository. These findings highlight significant gaps in metadata sharing, underscoring the need for standardized practices to improve metadata availability. Enhanced metadata reporting would foster data reusability, support better-informed decision-making, and promote reproducible research across the biomedical field.

23 November 2021 in bioRxiv
Verified
Preprint
Open access
PDF file
YHYu-Ning Huang
Yu-Ning Huang
PJPooja Vinod Jaiswal
Pooja Vinod Jaiswal
ARAnushka Rajesh
Anushka Rajesh
AYAnushka Yadav
Anushka Yadav
DYDottie Yu
Dottie Yu
SMSerghei Mangul
Serghei Mangul
Recent advances in high-throughput sequencing technologies have made it possible to collect and share a massive amount of omics data, along with its associated metadata. Enhancing metadata availability is critical to ensure data reusability and reproducibility and to facilitate novel biomedical discoveries through effective data reuse. Yet, incomplete metadata accompanying public omics data may hinder reproducibility and reusability by reducing sample interpretability and limiting secondary analyses. In this study, we performed a comprehensive assessment of metadata completeness shared in both scientific publications and/or public repositories by analyzing over 253 studies encompassing over 164 thousands samples, including both human and non-human mammalian studies. We observed that studies often omit over a quarter of important phenotypes, with an average of only 74.8% of them shared either in the text of publication or the corresponding repository. Notably, public repositories alone contained 62% of the metadata, surpassing the textual content of publications by 3.5%. Only 11.5% of studies completely shared all phenotypes, while 37.9% shared less than 40% of the phenotypes. Studies involving non-human samples were more likely to share metadata than studies involving human samples. We observed similar results on the extended dataset spanning 2.1 million samples across over 61,000 studies from the Gene Expression Omnibus repository. The limited availability of metadata reported in our study emphasizes the necessity for improved metadata sharing practices and standardized reporting. Finally, we discuss the numerous benefits of improving the availability and quality of metadata to the scientific community and beyond, supporting data-driven decision-making and policy development in the field of biomedical research. This work provides a scalable framework for evaluating metadata availability and may help guide future policy and infrastructure development.

25 November 2020 in OSF Preprints
Verified
Preprint
Open access
TRTejasvene Ramesh
Tejasvene Ramesh
KCKarishma Chhugani
Karishma Chhugani
VJVanessa Jönsson
Vanessa Jönsson
SMSerghei Mangul
Serghei Mangul
During the past decade, the rapid advancement of high-throughput technologies has reshaped modern biomedical research by vastly extending the diversity, richness, and availability of data and methods across various domains. Currently, computational researchers are empowered with data, methods, and tools that allow for the possibility of making important contributions in biomedicine –– through primary analysis of pre-clinical and clinical datasets, the application and development of novel machine learning algorithms towards task automation and diagnostic or treatment predictions, and secondary analysis of existing public omics data. Here we discuss the challenges and pitfalls researchers from dry labs are facing and how they are gaining independence and leading high impact projects.